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154 C. Castellani et al. / Journal of Cystic Fibrosis 8 (2009) 153–173AbstractThere is wide agreement on the benefits of NBS for CF in terms of lowered disease severity, decreased burden of care, and reduced costs. Risks
are mainly associated with disclosure of carrier status and diagnostic uncertainty. When starting a NBS programme for CF it is important to take
precautions in order to minimise avoidable risks and maximise benefits.
In Europe more than 25 screening programmes have been developed, with quite marked variation in protocol design. However, given the wide
geographic, ethnic, and economic variations, complete harmonisation of protocols is not appropriate. There is little evidence to support the use of
IRT alone as a second tier, without involving DNA mutation analysis. However, if IRT/DNA testing does not lead to the desired specificity/
sensitivity ratio in a population, a screening programme based on IRT/IRT may be used.
Sweat chloride concentration remains the gold standard for discriminating between NBS false and true positives, but age-related changes in
sweat chloride should be taken into account. CF phenotypes associated with less severe disease often have intermediate or normal sweat chloride
concentrations. Programmes should include arrangements for counselling and management of infants where the diagnosis is not clear-cut.
All newborns identified by NBS should be managed according to internationally accepted guidelines. CF centre care and the availability of
necessary medication are essential prerequisites before the introduction of NBS programmes.
Clear explanation to families of the process of screening and of implications of normal and abnormal results is central to the success of CF NBS
programmes. Effective communication is especially important when parents are told that their child is affected or is a carrier. When establishing a
NBS programme for CF, attention should be given to ensuring timely and appropriate processing of results, to minimise potential stress for families.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Neonatal screening; Diagnosis; Immunoreactive trypsinogen; Sweat test
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screening (NBS) date back to the early nineteen seventies, with
pioneering programmes examining the albumin content of
meconium [1]. The elevation of immunoreactive trypsin (IRT)
in the blood of neonates with CF and its measurement in dried
blood spots was first described in 1979 [2]. During the following
decade, the determination of IRT levels in heel blood was
introduced inAustralia, several European countries and elsewhere
[3–6]. Further improvement was possible after cloning of the
CFTR gene in 1989 [7–9], and subsequent identification of
common population specific CFTR gene mutations allowed
inclusion of DNA testing into screening protocols [10,11]. Since
then CF NBS has been gradually established across Europe,
initially rather slowly, but more recently at a faster pace. One
survey performed in 2004 [74] identified 26 screening pro-
grammes in Europe. Of these only two were nationwide (France
and Austria), the remaining 24 being either pilots and/or
regionally-based. These programmes screened more than
1,600,000 neonates per year, and detected annually over 400
affected babies. A subsequent survey in 2008 (unpublished data)
found that the number of infants screened had increased to more
than 3,000,000 per year, this being mainly due to the contribution
of the new UK and Russian national CF NBS programmes. This
trend is expected to continue in the forthcoming years, as more
European countries adopt CF as part of their NBS programme.
The proliferation of CF NBS programmes prompted the
European Cystic Fibrosis Society (www.ecfs.eu/) and the
European Coordination Action for Research in Cystic Fibrosis
(EuroCareCF, www.eurocarecf.eu/) to organise a dedicated
Consensus Conference. The International Society for Neonatal
Screening (www.isns-neoscreening.org), the EU EuroGentest
Network of Excellence (www.eurogentest.org), and the European
Molecular Genetics Quality Network (http://www.emqn.org)
were associated partners of this meeting, which took place in
Garda, Italy, on 28–29 March 2008. Its purpose was to establish
European Best Practice Guidelines for CF NBS. Altogether 37
experts in the field and professionals with an interest in CF NBS
were involved in pre-conference consultations and in the drafting
of preliminary documents. Thirty-one attended the meeting. The
conference addressed a wide range of issues, including the
rationale for CF NBS, technical issues, diagnostic criteria, and
communication with parents related to CF NBS. The following
document is a summary of the consensus achieved.
1. The rationale for CF neonatal screening
The effect of NBS for CF has been extensively studied,
and debated [12]. Two randomized controlled trials (RCTs)have been completed, one in the US [13,14] and one in the
UK [15,16], and examined children born within the 1985–
1994 and 1985–1989 periods respectively. Results of these
studies have been published and give good insight into the
potential advantages and hazards of CF NBS. Although these
analyses have shown benefits from CF NBS, particularly with
respect to better nutrition, some iatrogenic risks were
identified.
Another source of evidence to support CF NBS has been the
analysis of data from large clinical databases [17–19]. Finally
some evidence has been published from case or cohort studies
comparing historical controls, though these studies are
hampered by the overall improvements that have been
established for children with CF [20–24].
The available evidence supports CF NBS both with
respect to clinical outcomes and health economics. A CDC
workshop in the US also concluded that “on the basis of a
preponderance of evidence, the health benefits to children
with CF outweigh the risk of harm and justify screening for
CF” [25].
1.1. Benefits
1.1.1. Pancreatic disease
Determination of the presence of maldigestion enables the
pancreatic insufficient patient to be correctly treated with
enzyme replacement therapy and prevents unnecessary treat-
ment in patients with normal absorption [26,27].
1.1.2. Growth
A significant positive effect from NBS on height and weight
was observed in one of the RCTs and in 4 of 5 cross-sectional
studies [22,13,17,28–30].
1.1.3. Nutritional deficiencies
Deficiencies of proteins and fat-soluble vitamins have been
described in clinically diagnosed CF patients [31], whilst CF
NBS can prevent morbidity due to these deficiencies [31]. In a
RCT the NBS group had higher levels of vitamin E than the
clinically diagnosed group. However, cognitive development
was not significantly improved in patients identified by
screening [32].
1.1.4. Lung involvement
In the Wisconsin RCT, the NBS group had fewer CF changes
on their chest radiograph at diagnosis, but this was not sustained
as the children grew older. This may relate to the fact that an
increased number of children in the NBS group were infected
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in one of the two participating centres). In all cohort studies
significantly better chest radiograph scores were found in the
NBS groups. Cross-sectional studies using data from US data-
bases demonstrated better lung function for both the 6–10 years
and 11–20 years NBS age groups [31]. In addition, fewer
patients detected through NBS had an FEV1 below 70%
predicted [18]. In a UK database study screened and
unscreened patients showed no differences in lung function,
but this was achieved by significantly less treatment in the
screened cohort compared to those diagnosed clinically [33]. A
Dutch cohort study showed better lung function for the
screened cohort until the age of 12 years [20], and an
Australian study showed benefit that persisted at 15 years of
age [23].
1.1.5. Burden of care
In the UK RCT [15] and in two observational studies [28,31]
non screened patients with a clinical diagnosis had 2–3 times
more hospital admissions than patients identified by NBS. A
lower intensity of intravenous and nebulised treatment was
found in screened infants compared to non-screened with a
similar CFTR genotype, although the two cohorts had similar
clinical condition. This suggests that the burden of care is
reduced for families of screened infants [33,30].
1.1.6. Psychosocial effects
Delayed diagnosis of a CF child whilst symptomatic may
result in long term adverse psychosocial effects, which affect the
parent–infant bond, and lead to less confidence in medical
caregivers.Most parents of clinically diagnosed patients with CF
recall the long period of uncertainty and anxiety preceding the
diagnosis and would have preferred an earlier diagnosis [34].
Parents whose child was identified early via CF NBS experience
less parental stress than parents of patients who were diagnosed
clinically [35–37].
1.1.7. Survival
In the Wisconsin RCT no survival-analysis was performed
(although data have been available for subsequent reviews), and
in the UK RCT a lower risk of premature death was found in
patients detected by NBS, although the small numbers mean that
these results need to be viewed with caution [16]. A systematic
literature review of mortality reported a lower CF-related
mortality risk in screened cohorts [19].
Box 1
CF NBS, when associated with early treatment
limits lung damage in childhood, reduces the burden
of care for families and may improve survival. NBS
has a beneficial effect on nutritional status, with
improved growth, height and weight, and may
prevent deficiency of fat-soluble vitamins and protein
malnutrition. An early diagnosis by CF NBS results in
less parental stress compared to a delayed diagnosis.1.2. Hazards
1.2.1. Anxiety
False positive results are a challenging problem in all NBS
programmes. Parents of non-affected children with an elevated
IRT,who have been sent for a sweat test, may access inappropriate
information about CF on the internet and/or from acquaintances.
Short-term extreme anxiety and feelings of depression have been
reported among parents awaiting definitive diagnostic assessment
[38,39], and in a minority of cases anxiety may persist for some
considerable time despite a negative sweat test [40]. The period
between informing the family of a positive screening test result
and the definitive diagnostic assessment should be as short as
possible. Concepts of positive and negative NBS results can be
very confusing to parents, and effective communication is crucial
in this context (see Section 4).1.2.2. Knowledge of carrier status
NBS protocols that include CFTR mutation analysis identify
non affected heterozygous newborns. Parents and the extended
family members are offered genetic counselling and DNA testing,
and in a small number of cases both parents will eventually be
identified as carriers. This may in turn lead to better informed
reproductive choices in subsequent pregnancies. However, in most
cases only one parent will be identified as a carrier. These couples
will be left with a probability of an affected child in further preg-
nancies higher than the general population, though the precise risk
is difficult to assess and depends on gene frequencies in that pop-
ulation [41]. Furthermore, from the child's perspective the knowl-
edge of being a carrier is not of direct and immediate benefit, and
as the child could not decide whether he/she wished to be tested,
this can be considered as a violation of the “right-not-to know”.1.2.3. Inconclusive NBS results
Occasionally, infants are identified by NBS in whom a CF
diagnosis can neither be confirmed nor excluded. They usually
have raised IRT values, normal or borderline sweat chloride
concentrations, and carry a CF-causing mutation, sometimes with
another CFTR mutation with unclear or unknown pathogenic
potential [42,43]. Although these newborns are usually healthy at
diagnosis, they may be susceptible to a CFTR-related disorder, a
condition associated with CFTR mutations, but where a diagnosis
of CF cannot be made because the individual does not meet
standard diagnostic criteria [43,42]. Although these infants show
little or no sign of disease, the long-term consequences may be
variable, and some of them may over time develop features
associated with CF [44,45]. Such variability makes it challenging
to predict clinical outcome, and difficult to provide genetic counsel-
ling for the family [46,47]. Families of these infantsmust have clear
information and follow-up in a CF clinic may be appropriate in
order that early signs of CF are recognised and treated promptly.
However this needs to be balanced against the impact on the family
of not knowing if their child will develop CF. The impact of
diagnosis in these cases will also depend on how local health care
is funded and the effect on medical insurance. Further suggestions
on how to manage these infants are described in Section 3 [48].
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A lower percentage of NBS patients with chronicP. aeruginosa
infection has been repeatedly reported [18,21,31,33]. However, in
the Wisconsin RCT, NBS patients acquired chronic infection with
P. aeruginosa at an earlier age than clinically diagnosed patients.
This findingmay relate to cross-infection from older CF-patients in
a small waiting area in one of the twomain CF clinics inWisconsin
and highlights the potential risk that NBS infants face through early
exposure to a medical environment [14]. Ensuring sensible
measures to prevent cross-infection will hopefully reduce this
risk considerably.
1.2.5. Potential for ethnic discrimination
The use of the IRT/DNA approach in a multi-ethnic
community will not identify patients with mutations specific to
some ethnic origins. In a European survey of mutations in CF
patients of North-African and Turkish origin only 50% of the
mutations in patients of Turkish descent would be detected using
standard mutation panels [49,50]. This is an issue for countries
and/or large cities with multiple ethnicities. Some current
programmes using IRT-DNA-based protocols attempt to
compensate for this by retaining a second-sample IRT tier for
infants in whom no CFTR mutation is recognised but the first
IRT sample was very high [51,52].
Box 2
To run an effective NBS programme for CF it is
essential to recognize some of the potential hazards
that exist. A false positive screening test may lead to
emotional distress in parents andmeasures should be
taken to reduce the adverse effects on false
positives, by ensuring that a rational protocol is
followed, and that results are processed promptly. A
clear algorithm must be followed to evaluate and
manage infants with an equivocal diagnosis follow-
ing NBS. Efforts should be made to reduce the
negative impact of carrier recognition and infants
with a positive diagnosis should bemanaged in away
that does not expose them to unnecessary harmsuch
as cross-infection.1.3. Costs
CF NBS costs may vary considerably, and are difficult to
quantify. Countries or regions contemplating CF NBS should
consider both implementation and management costs:
1.3.1. Implementation costs
• Production of leaflets explaining CF NBS for health
professionals and for parents (both antenatal and for various
possible results, including carrier status).
• Modification of the neonatal blood spot cards (i.e. Guthrie
cards) to accommodate the need for extra blood, especially if
they have to be sent to different laboratories for IRTand DNA-testing, and training of staff who undertake NBS sample
collection, to ensure appropriate samples are collected for IRT
analysis.
• Training of maternity and community health professionals (a
sustainable system of CPD needs to be established) in order
that appropriate advice is available to parents regarding NBS
for CF.
• The equipping and staffing of laboratories to ensure
appropriate standards both for IRT and for molecular genetic
testing.
• A system for the prompt assessment of infants with a positive
screening test (including the capacity to undertake valid
sweat testing).
• Preparation of local CF-teams to manage the early care of
infants diagnosed following NBS.
• A support structure for families who opt for genetic
counselling if their infant is recognised as a carrier.1.3.2. Management costs
NBS for CF at birth can be added to standard NBS
programmes such as phenylketonuria, congenital hypothyroid-
ism, and galactosemia. Long-term costs include consumables
(test reagents/assays) and staff. These depend to some degree on
the NBS protocol adopted.
A study compared the health effects of four screening
strategies on a hypothetical cohort of 200,000 infants [53]. In
the model, “gain in lifetime” was used as a measure of the effect
of NBS, assuming a 50% reduction of an estimated mortality in
early childhood of approximately 6%. Mortality is a rather blunt
outcome and not reflective of current CF care aspirations, but
other outcomes were difficult to quantify in economic terms and
were not included. The most favourable cost-effectiveness ratio
was found for the IRT/IRT strategy, whilst the widespread used
IRT/DNA approach had the least favourable cost-effectiveness
ratio. The study demonstrates that if treatment costs of patients
identified by neonatal screening are reduced by 10% over their
lifetime, then NBS for CF would result in financial savings as
well as in gain-of-life years.
The need for therapymay decline in a significant proportion of
the pre-school age group as the focus will shift from disease
control in clinically affected babies to health maintenance and
vigilance. Evidence shows that costs associated with treatment of
CF infants detected through NBS are significantly lower than
those of their counterparts detected clinically during early
childhood. A retrospective cohort study has provided useful
data to support the argument that CF NBS reduces the treatment
costs of people with CF. [33] The study compared a group of 184
NBS infants in the UK with 950 infants identified by clinical
presentation. Fifty percent of screened infants cost less than
$ 1000 per annum in prescribed drugs whereas only 25% of
clinically presenting infants were in this low cost group (Fig. 1).
Fifty percent of clinically diagnosed patients cost more than
$10,000 (compared to 25% of the NBS group). These results were
confirmed when an equivalent severity of CFTR genotypes were
considered. The same authors also found that nebulised therapy, a
surrogate marker for lung damage, was significantly less in the
Fig. 1. Therapeutic costs in infants diagnosed by neonatal screening (NBS) and
presenting clinically (CD). The apparent paucity of dots on the left is an illusion
because the ‘missing’ data points lie on top of each other in the lower cost
categories. Reproduced with permission from [33].
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diagnosed clinically (Fig. 2) [30].
Box 3
To ensure effective performance of a new pro-
gramme for CF NBS, adequate resources are required
for training and capital costs. However, once estab-
lished CF NBS is cost-effective, because children
identified by NBS cost less to treat.Fig. 2. Accumulation of nebulised drugs in cohorts of infants with CF. Screened
(NBS) cohorts accumulate compared to either those presenting with symptoms
within the same time period as NBS (early-CD, first two months of life) or
those presenting clinically after two months of age (late-CD). Reproduced with
permission from [30].2. Protocols and technical issues
All screening programmes aim at maximising diagnosis of
CF and minimising second heel-pricks, unnecessary sweat tests,
detection of unaffected carriers, and recognition of infants with
an equivocal diagnosis. Besides, as there is much evidence that
early diagnosis is beneficial, and that diagnosis before 2 months
of age gives greatest benefit [30], CF NBS should be organised
so that results are available for a timely assessment and sweat
test to confirm a diagnosis as promptly as possible (certainly no
later than two months of age and preferably in the first month).
There are many different protocols across Europe for CF
NBS. This reflects 1) the ethnic mix of populations 2) the
structure of current NBS protocols (for instance the ability to
organise a second heel prick test) and 3) variations in healthcare
provision and resource. Whilst some harmonisation of protocols
is desirable, it is not realistic to hope for a single European
scheme and probably not desirable. It is important however to
compare rigorously the performance of different protocols.
All current protocols rely on IRT as the primary test and on
sweat test for confirming or excluding the diagnosis of CF.
Intermediate tiers are required to achieve an acceptable
combination of sensitivity and specificity. These tiers may
consist of CFTR mutation analysis on the first blood spot, a
second IRT testing on another blood spot collected later on, or
various combinations of these two. An algorithm for a standard
CF NBS procedure is shown in Fig. 3, and some examples ofintermediate tiers strategies in Fig. 4. CF NBS protocols
currently used in Europe are shown in Table 1.2.1. The first tier: IRT
2.1.1. IRT cut offs
The initial IRT centile cut-off has the greatest effect on NBS
performance, and therefore optimization of cut-off levels
depends on the relative importance attached to sensitivity and,
particularly, specificity. Early experience with the two-stage
IRT–IRT protocol [54,55] showed that good sensitivity can be
achieved with a 99.5th centile cut-off, although the use of a
lower cut-off (e.g. 99th centile) is also common [56]. A
retrospective study of false-negative cases suggests that when
the sample is taken relatively late (day 5), lowering the cut-off
would have little effect on sensitivity (Heeley, unpublished
data). Furthermore, using low cut-offs, around the 95th centile,
prior to second tier mutation analysis, reduces the positive
predictive value that identifying a single CFTR allele has with
regard to making a subsequent diagnosis of CF.
In general, a policy of replication in duplicate should be adopted
for all samples with IRT above a preliminary threshold, usually set
10 ng/ml below the final cut-off. This is to minimise effects of
volumetric variability of the punched discs, day-to-day variation in
IRT assay calibration, and to detect contamination of the sample
with faeces or possibly sample misidentification.2.1.2. Quality control
There are significant differences among commercially
available IRT assay kits in terms of the value assigned to the
initial cut-off and possibly also in the rate of decline of
measured IRT in positive cases during the first few weeks of life
[57,58]. Despite such variability, all the current commercial IRT
assays seem to produce satisfactory results.
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extremely difficult as commercially available trypsin preparations
differ between companies and batches in immunogenicity, protein
concentration, or tryptic activity [59]. Traditional EQA schemes
are of limited use for calibrating IRTassays used in screening since
there is too much volumetric variability in the control spots
themselves and in the calibrant spots used to construct the standard
curve. A large number of spots assayed in several different daily
runs would be needed in order to produce accurate results.
An alternative approach is to use the population distribution
of IRT values to monitor assay performance. Centile plots of
IRT results from routine screening are useful as a retrospective
check on assay calibration, and will detect quite small
differences between individual batches or between different
laboratories [60]. This overcomes difficulties associated with
prepared blood spots and, provided that a sufficient number of
results is available (at least over 2000), has greater statistical
validity than EQA based on relatively few blood spots [60].
2.1.3. Age at sampling
The age at which the blood sample is taken seems to have
little direct effect on the effectiveness of screening. Some US
programmes sample on day one of life and report reasonableFig. 3. Standard CF NBS procedure. ⁎Some mutations like 3849+10 Kbresults, as does the relatively late day 5 sampling [13,58]. The
introduction of CF screening does not require a change in
current blood sampling practice except for additional emphasis
on avoiding fecal contamination.2.1.4. Stability of IRT in blood spots
IRT in dried blood spots is stable over the short term, but it is
inadvisable to rely on a screening result from a sample that has been
significantly delayed in transit. When stored for 10 weeks in the
dark at room temperature and in a dry location inside a cardboard
box, ‘Guthrie’ blood samples from normal babies lose approxi-
mately two-thirds of their IRT as measured by Sorin® reagents,
which measure mainly trypsinogen and give a screening cut-off
~80 ng/ml [61]. The Lille group [62] studied samples stored at
+4 °C using the Boehring RIA-gnost® neonatal trypsin kit which
detects both trypsin and trypsinogen and inhibited forms of the
enzyme and has a screening cut-off of approximately 900 ng/ml.
After 4 months samples from babies with non-CF hypertrypsinae-
mia had lost approximately 25% and after 8 months almost 45% of
their activity. Unlike samples from normal neonates, samples from
CF case showed a bimodal decay curve suggesting a different mix
of IRT species.CNT or R117H may be associated with sweat chloride b30 mmol/L.
Fig. 4. Three examples of intermediate tier strategies. ⁎ the cut-off for resampled IRT is lower than the cut-off for IRT at birth. ⁎⁎ if IRT at birth exceeds a cut-off higher
than the one used to start the procedure, the protocol proceeds to resampling even though no mutations were detected.
160 C. Castellani et al. / Journal of Cystic Fibrosis 8 (2009) 153–1732.1.5. Non-CF causes of increased IRT
A wide variety of physiological or medical conditions have
been associated with hypertrypsinaemia in the neonatal period.
Increased IRT has been noted in trisomies 13 [63] and 18 [64].
Perinatal stress has also been reported to be a significant factor
in hypertrypsinaemia [65], and a cohort of 372 sick infants on
the neonatal intensive care ward had significantly increased
blood-spot IRTcompared with normal infants irrespective of the
diagnostic category [66]. However, neonatal infection as such
was reported not to have any effect [67]. Elevated IRT levels
have been found in association with congenital infections, renal
failure and bowel atresia [57] and in a case of nephrogenic
diabetes insipidus [68].
In the absence of any of the common CF causing mutations,
and particularly if the mutation panel has a sufficiently high
population specific detection rate in the newborn ethnic group,
the likelihood of CF in such cases is low.
The population distribution of blood IRT concentrations in
the newborn period is slightly higher in babies of North African
parentage [69] and in African-Americans [70] than in babies of
North European origin.
2.1.6. IRT in special situations
A tendency for CF neonates with meconium ileus to have
IRT values within the normal range was noted early in the
history of newborn screening, though its basis is obscure
[58,71,52].
Hyperechogenic bowel on ultrasound imaging in utero in the
second trimester of pregnancy may indicate CF, with risk of the
disease in the fetus ranging from 1.5% to 25% depending on the
grade of echogenicity observed [72,73].Neonates presenting with meconium ileus, who have had
hyperechogenic bowel in utero, or are known to be at high risk
due to family history should be regarded as high risk and should
be investigated independently, in parallel with the normal NBS
process.
2.2. Intermediate tiers
Second tiers can be either (i) IRT on a second blood sample,
taken at three to four weeks of age, assayed in duplicate
following the same procedure as for the initial assay or (ii) CFTR
gene mutation analysis using the initial blood spot or (iii) PAP
analysis using the initial blood spot [12,74]. Many CF NBS
strategies use various combinations of these.
2.2.1. Second sample IRT assay
The concentration of blood/serum IRT declines with age
much faster in false positive cases than in infants with CF [3],
and therefore raised IRT at about one month of age has high
positive predictive value. Most programmes select a slightly
lower cut-off for this second sample.
The rate of decline of IRT in babies with CF is variable. In
the CF group as a whole IRT is still increased at one year of age
[75,76] but such patients typically have non-detectable levels of
IRT by five years of age [75–77]. However, a significant
proportion of CF patients show a more rapid decline in IRT:
Rock MJ [78] found that of 24 neonates who were positive on
the initial screen, 10 had IRT values below the cut-off in
samples taken between 41 and 62 days of age. Retrospective
genotyping of babies with raised IRT in the initial sample but
IRT below the cut-off in a second sample taken at 27 days of age
Table 1
CF NBS protocols used around Europe.
Areas Average screened population per year 2nd tier 3rd tier 4th tier Specifics
Two-tier protocols
Liguria (I) 12,000 ST – –
Three-tier protocols
Czech Rep 76,000 MUT ST – PS; February 2005–November 2006
Emilia Romagna (I) 40,000 rIRT ST –
Calabria (I) 18,000 rIRT ST –
MUT
Lombardy (I) 98,000 MUT ST – rIRT if bIRT N97.5° centile
rIRT MUT if bIRT N99° centile
Marche (I) 14,000 MUT ST – PS; rIRT if bIRT N97.5° centile
MUT if bIRT N99.8° centile
rIRT
Tuscany (I) 33,000 MP ST –
rIRT
Piedmont (I) 39,000 MUT ST – PS; rIRT if bIRT N98.6° centile
rIRT MUT if bIRT N99.6° centile
Lazio 1 (I) 28,000 rIRT ST –
MUT
Lazio 2 (I) 37,000 MUT ST –
rIRT
Sicily (I) 54,000 MUT ST –
rIRT
Austria 77,000 rIRT ST –
Catalunya (SP) 83,000 rIRT MUT –
ST
Castilla-Leon (SP) 18,000 rIRT ST
MUT
Galice (SP) 21,000 rIRT MUT – PS
ST
Wales (UK) 34,000 MUT ST
Dresden (GER) 15,000 MUT Since January 2008 IRT PAP
Heidelberg (GER) 40,000 MUT ST PS (started April 2008)
PAP
Russia 1,300,000 rIRT ST
Four-tier protocols
France 809,000 MUT rIRT ST rIRT if MUT-tive and bIRT N100 μg/l
Poland 168,000 MUT rIRT ST rIRT if MUT-tive
England (UK) 655,000 MUT rIRT ST rIRT if 1 mutation at MUT or bIRT N99.9th centile
MUT Expanded MUT if one mutation at first panel
Northern Ireland (UK) 24,000 MUT rIRT ST rIRT if 1 mutation at MUT or bIRT N99.9th centile
MUT Expanded MUT if one mutation at first panel
Four-tier protocols
Scotland (UK) 58,000 MUT rIRT ST rIRT if 1 mutation at MUT or bIRT N99.9th centile
MUT Expanded MUT if one mutation at first panel
Veneto 56,000 MUT rIRT ST rIRT if MUT and MP-tive and bIRT twice the cutoff
Trentino Alto-Adige (I) MP
Notes:
- 1st tier is always IRT (bIRT).
- abbreviations: rIRT = IRT resampling; MUT = genetic analysis; MP = meconium proteins dosage; ST = sweat test; NA = not available; PS = pilot study; PAP =
pancreatitis associated protein.
- more than one test per tier is considered if tests are performed at the same time.
Modified and updated from [74].
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heterozygote for the F508del mutation and another CFTR
mutation, the majority being R117H [79].
2.2.2. CFTR mutation analysis
Most NBS protocols use analysis of a panel of CF-causing
mutations [80] on samples with a raised IRT. Homozygotes andcompound heterozygotes can be assessed promptly and
following a confirmatory sweat test, management initiated
often in the first three weeks of life. Infants carrying only one
identified mutation proceed in the protocol, usually through a
sweat test, in order to distinguish affected individuals from
carriers. DNA-testing should always be linked to genetic
counselling in order to provide sufficient advice to the family
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are within the reproductive age.
A second tier NBS panel should be designed in order to
include well known CF-causing mutations represented in the
local CF population, including those alleles frequently occur-
ring in ethnic minorities. However, population genetic calcula-
tions based on the Hardy–Weinberg law provide evidence that
increasing mutation coverage much above 80% has little effect
on false negative rates. In fact, above such threshold the
proportion of babies with only one mutation detected who are
affected with CF falls markedly, whilst the number of
unaffected carriers detected keeps increasing in proportion to
the mutation detection rate (Fig. 5). In areas with ethnic
diversity and a tendency to marry within ethnic groups the
Hardy–Weinberg equation does not apply. Here, increasing the
number of mutations has a clear benefit on screening
performance. Additionally, in such areas there is also an ethical
and political dimension to ensuring that minority groups are not
disadvantaged.
It is still a matter for discussion whether the R117H mutation
should be included in a second tier NBS panel or not. R117H
can be in cis, i.e. on the same parental allele, with a stretch of
either 5 or 7 thymidines located in intron 8, conventionally
named T5 or T7 [81]. These polymorphic tracts affect the extent
of correct splicing of CFTR exon 9: T5 stretches give rise to less
efficient splicing than T7 [82–84]. Thus, R117H-T5 will result
in less functional CFTR than R117H-T7 [82]. In clinically
diagnosed CF patients populations, when found in compound
heterozygosity with a CF-causing mutation R117H-T5 gen-
erally results in pancreatic sufficient CF, whilst R117H-T7 may
result in a mild form of CF, obstructive azoospermia, or no
disease at all [43]. In the French NBS programme [52], up to 7%
of the newborns who have an elevated IRT test and two CF
alleles are compound heterozygous for R117H-T7 and a CF-
causing CFTR mutation, a much higher proportion than in the
CF population diagnosed clinically [85]. These children have
shown no major signs of CF, although longterm outlook is
difficult to predict and there are reports of significant chest
involvement with this genotype and manifestations of CF
disease in adulthood [86].Fig. 5. Effect of CFTR mutation coverage on yields. The data shown are
calculated using the Hardy–Weinberg equation for a population where 0.5% of
the initial screening samples are sent for a single-stage mutation analysis. It is
assumed that carriers for all the mutations examined are over-represented to the
same extent as carriers of F508del.Requirements regarding parents' consent to potential genetic
analysis at the moment of the blood collection vary from
country to country but may be very onerous [87]. Usually an
“opt out” scheme is utilised at maternity wards that explains the
entire CF NBS scheme, including the potential of a secondary
“CFTR-gene specific” genetic test.
2.2.3. PAP analysis
The use of the pancreatitis-associated protein (PAP) as a
second tier, or even combined with IRT in the first tier is being
explored. This approach would avoid the issues raised by CFTR
mutation analysis or the need for a second blood sample. A
combined IRT+PAP assay kit is being developed and pilot
studies are planned or in progress in the Netherlands, in Germany,
and in France (Jeannette Dankert-Roelse, Olaf Sommerburg and
Jacques Sarles personal communications).
Box 4
The goal of screening should be to find the greatest
proportion of CF-patients as possible with the least
number of false positive tests at an affordable price.
This can be accomplished using different screening
protocols. As NBS priorities may vary from region to
region in terms of funding, ease of blood sample
collection, ease of access to clinical services, and
CFTR mutation distribution, a complete harmonisa-
tion of protocols is neither desirable nor possible. The
choice of strategy will depend upon population
genetics, costs, the weight placed on the different
aims: maximal sensitivity, minimal or no resampling
needed, rate of unwanted carrier detection, and re-
duced numbers of sweat tests.
3. Diagnosis through CF neonatal screening
Screening tests identify apparently healthy individuals
who have a high probability of having a specific disorder,
which justifies a subsequent diagnostic procedure [88].
Following a positive NBS for CF, a major component of
the subsequent assessment is a sweat test, which can usually
distinguish between true and false positives. Despite
recognition of the CFTR gene defect, the sweat test is still
considered by consensus groups as the ‘gold standard’ for a
diagnosis of CF. Infants with a positive NBS test and a raised
sweat chloride (above 60 mmol/L) are considered to have a
diagnosis of CF, even in the absence of any clinical features
[42,89].
After a positive screening test result is reported the time to
diagnostic assessment should be as short as possible. This
requires efficient cooperation between screening laboratories,
maternity units, community health care providers and CF
centres. It is essential that these pathways are established before
implementation of a CF NBS programme. In particular,
attention should be given to ensure that the assessment and
sweat testing are carried out promptly to minimise parental
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abnormal screening test result [90].3.1. Sweat test
The sweat test is a key component of any NBS protocol for
CF, providing a physiological confirmation of the screening
result, or reassurance that a carrier is not a compound hetero-
zygote with an as yet unidentified CFTR mutation. However,
sweat testing in this age group is challenging and has to be
performed according to specific guidelines [42,91].
The following must be taken into account when undertaking
a sweat test in infants following a positive screening result:
• Sweat chloride concentration is the “gold standard” analytical
measure to confirm a diagnosis of CF in NBS positive infants.
With rare exceptions, a diagnosis of CF can be made when
chloride levels exceed 60mmol/L, and excludedwhen they are
below 30 mmol/L [89,42]. Results which are not physiologi-
cally compatible should be questioned (i.e. chloride or sodium
N150 mmol/L).
• Sweat collection and analysis should be performed in a
laboratory with adequate experience. International standardsFig. 6. Diagnostic algorithm for inconclusive diagnosuggest that a laboratory should be undertaking at least 50
tests per year [91,92].
• When using a 2×2-inch gauze or filter paper, the minimum
sweat weight should be 75 mg. When using the coiled
capillary system (MacroductTM), the electrodes and stimu-
lation area are smaller and the minimum acceptable sample is
15 μL (calculated to ensure a rate of sweat secretion greater
than 1 g m−2 min−1).
• Sweat testing can be performed by the age of two weeks in
newborns weighing 3 kg or more [91]. Neonates must be
normally hydrated and with no significant signs of systemic
illness. When clinically indicated, it can be performed in
term infants after 7 days of age, but with a higher probability
of insufficient sweat collection.
• Collecting sweat from two sites is preferable as this reduces
the number of insufficient samples and provides internal
validity. Sweat should be collected for not more than 30 min
and not less than 20 min. Insufficient sweat collections
should not be pooled; the test should be repeated.
• Sweat sodium is also elevated in CF but is less discrimina-
tory when compared to chloride, and therefore should not to
be used for the diagnosis of CF [92].
• Sweat conductivity should not be used to confirm a diagnosis
of CF.ses following CF NBS. Reproduced from [48].
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particular, 3849+10 kb CNT) can be associated with normal
or equivocal sweat electrolyte values.
• Following sweat collection, chloride analysis should be
undertaken promptly (preferably immediately) in order to
reduce the waiting period for the family.Box 5
The sweat test remains a key component in
establishing a diagnosis of CF in infants with a
positive NBS result. Sweat collection in infants is
challenging, and must be performed according to
specific guidelines.Table 2
Clinical features consistent with a diagnosis of CF following newborn screening.
Respiratory
1. Symptoms
a. Cough
b. Wheeze
2. Clinical findings
a. Over-expanded chest
b. Crackles
c. Wheeze
d. Tachypnoeic
e. Abnormal chest shape
3. Chest radiograph changes
a. Overinflation
b. Increased markings
c. Areas of collapse or consolidation
4. Chest high resolution computerised tomogram (HRCT) changes
a. Air trapping
b. Early evidence of airway inflammation/bronchiectasis
5. Positive respiratory culture for characteristic CF pathogens
a. Cough swab/plate
b. Broncho-alveolar lavage
Non-respiratory
1. Clinical evidence of malabsorption
a. Meconium ileus
b. Poor weight gain
c. Distended abdomen
d. Loose offensive stool
e. Poor head growth
f. Rectal prolapse
2. Laboratory evidence of malabsorption
a. Low fecal elastase (or chymotrypsin)
b. Positive fat microscopy
c. Low fat soluble vitamin levels
3. Radiological evidence of pancreatic disease
a. Pancreatic calcification on Abdominal radiograph
b. Pancreatic fibrosis on abdominal ultrasound scan
4. Liver disease
a. Prolonged cholestatic jaundice
b. Elevated liver enzymes (ALT/AST)
c. Abnormal liver appearance on ultrasound scan
5. Salt loss
6. Absence of the vas deferens
Reproduced from [48].3.2. Inconclusive diagnosis
The majority of affected infants recognised through NBS
have a clear diagnosis of CF (i.e. two CF-causing mutations in
trans or one recognised CF-causing mutation and a sweat
chloride level above 60 mmol/L) [42]. However, in a small but
significant number of cases the diagnosis is equivocal,
specifically when CFTR mutations with unclear phenotypic
consequence are detected or when one mutation is found and
sweat chloride levels are in the intermediate range (i.e. between
30 and 60 mmol/L).
The ECFSCFNBSWorking Group has produced a consensus
with regard to the evaluation and management of infants with an
equivocal diagnosis following CF NBS [48]. Initial statements
were agreed based upon a systematic review of the literature, and
formed the basis of a modified Delphi methodology [93] to
achieve a Europewide consensus. Contributing clinicians,
biochemists and geneticists were asked to express their opinions
on the statement. Their options were either to agree, disagree or
state that they felt unable to comment. If they disagreed they were
asked for comments or alternative suggestions. Consensus was
established if more than 80% of respondents agreed with a
particular statement.
Fig. 6 illustrates the pathway developed through the consensus
process. Highlighted (shaded) boxes are discussed below.
Repeat sweat test— Sweat collection and analysis should be
repeated in an experienced laboratory.
Extended DNA analysis — Further DNA analysis of the
CFTR gene should be guided by the type of screening protocol
(i.e. protocols that initially only examine for a limited panel of
CFTR mutations would prompt further DNA analysis with an
extended panel of population specific mutations). The extent of
DNA analysis should reflect the level of clinical suspicion. Care
should be taken to avoid a situation where mutations are
recognised with an unclear pathogenic potential (e.g. missense
mutations identified by sequencing of the CFTR gene), although
in the near future this may become unavoidable, particularly asadvancing technologies allow for easier and less costly
comprehensive CFTR gene sequencing or scanning. Infants
recognised to be compound heterozygotes for R117H should
have further characterisation of the poly T variant region, and
of the preceding TG repeats if found to be in cis on a 5T
background [94].
Baseline clinical assessment — Although infants with CF
may have little or no symptoms in the first months of life, it is
essential to carefully search for clinical features associated with
the diagnosis of CF (Table 2). Clinical evaluation should be
done at a CF clinic, and include assessment of non-respiratory
(e.g. fecal elastase examination) and respiratory disease
(airways culture and chest radiograph) signs of the disease.
Further investigations may be indicated as determined by the
clinical symptoms.
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physiological techniques are available to demonstrate the salt
transport defect that characterises CF. Some of these tests are
technically challenging in neonates/infants, and they are
currently undertaken only in few specialist centres worldwide.
Thus far, none have the validity of sweat testing or CFTR
genotype analysis, but may provide useful additional informa-
tion in equivocal cases (Table 3).
Box 6
Statements have been developed that will guide
physicians in the management of infants with an
equivocal diagnosis following NBS for CF.3.3. Clinical follow-up
The implementation of a dedicated CF NBS programme
shifts the focus of CF health care from control of disease
manifestations in symptomatic children to health keeping in
asymptomatic infants. This in turn implies the availability of a
follow up programme to be promptly implemented after the
early diagnosis, and so an important part of the programme is to
have clearly defined referral pathways to specialist CF services.
The Consensus acknowledges the necessity to achieve a pan-
European agreement on clinical follow up practice. Expert
opinions on the clinical management of infants identified
following CF NBS are in the process of being collected, again
through a modified Delphi methodology [93].
Although a general agreement on aspects of standard care
may be established, the lack of an evidence-base approach
makes it very difficult to produce definitive statements onTable 3
Electrophysiological diagnostic techniques.
Test Technical details Wh
Nasal Potential Difference (PD) Ion transport across airway epithelium
can be assessed by measuring the
baseline PD. The impact on the PD
of perfusing different solutions and
drugs provides further information
to differentiate CF from non-CF
recordings.
The
the
plac
abra
are
be s
Intestinal Current Measurements (ICM) A biopsy is mounted in the laboratory
in a device (Ussing chamber) that
enables measurement of transepithelial
ion transport. Various aspects of ion
transport can be examined.
Bio
is p
infa
anae
Small bowel biopsy Similar measures of transepithelial
transport processes can be
undertaken in the laboratory on
upper gastro-intestinal (GI)
mucosal biopsies.
Upp
anae
Reproduced from [48].
a For details of centres in Europe that undertake appropriate electrophysiological i
CF Society Diagnostic Network (michaelwil@hadassah.org.il).several issues. RCTs are needed, but also difficult to implement
because of poorly defined clinical outcome measures and the
good outlook for infants recognised through NBS. In CF infants
detected by NBS lung disease is generally mild or even absent,
and pulmonary outcomes traditionally used in older populations
are relatively insensitive and provide poor diagnostic accuracy.
Longitudinal studies aimed at the development of new surrogate
outcome endpoints and at the establishment of standardised
operating procedures are underway. Presently, research is
focused on imaging studies capable of measuring structural
changes preceding either respiratory symptoms or functional
changes [95], infant pulmonary function testing [96], and pro-
and anti-inflammatory cytokines collected by broncho-alveolar
lavage in asymptomatic infants [97–99].
The implementation ofNBS programmes for CF across Europe
increases the potential for organising large multi-centre trials that
recruit infants and answer some of the questions concerning their
management. Some of these issues are listed below.
3.3.1. Staphylococcus aureus prophylaxis
It is yet unclear whether anti S. aureus prophylaxis should be
recommended in the first years of life. Two controlled studies
versus placebo have demonstrated the decreased prevalence of
S. aureus colonisation in babies treated with either flucloxacillin
or cephalexin [100,101]. However, the high rate of P. aerugi-
nosa colonisation in patients treated for 5 to 7 years with
cephalexin gives cause for concern [101], although this has not
been seen in studies using a narrow spectrum anti-staphylo-
coccal antibiotic such as flucloxacillin [102].
3.3.2. Anti-RSV immunisation
Immunoprophylaxis with palivizumab may prevent severe
RSV infection and has been shown to significantly reduce
hospitalisation of infants with chronic respiratory disease [103].at it involves for the infant Availability a
exploring electrode is placed in
nose. A reference electrode is
ed either subcutaneously or over
ded skin on the forearm. Solutions
perfused into the nose and can
wallowed.
Very few centres are able to undertake
this measurement in infants although
it is more widely available in older
children and adults.
psy of rectal mucosa. This procedure
ainless and well tolerated by young
nts. Does not require general
sthesia or sedation.
This technique requires a dedicated
laboratory service with highly skilled
technicians. Available in limited number
of centres in Europe.
er GI biopsy; requires general
sthesia in most cases.
Limited (only currently available
in Sheffield, UK; contact
Prof Chris Taylor).
nvestigations on infants, contact Dr Michael Wilschanski, chair of the European
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been published, although RSV infection is associated with
severe respiratory distress in this population [104].
3.3.3. Physiotherapy management of asymptomatic infants with
CF
It is not known whether commencing physiotherapy in
apparently healthy babies at diagnosis will have any effect on
slowing the progression of the disease [105]. Long-term trials
are needed to evaluate whether a routine regimen of airway
clearance in asymptomatic infants is of long-term benefit.
3.3.4. Vitamin K supplementation
Vitamin K supplementation is recommended at all ages, but
there is still no standard dosage validated for vitamin K therapy
in infants.
Multicentre trials examining S. aureus antibiotic prophylaxis,
P. aeruginosa eradication, and Dornase alpha use in infants
diagnosed with CF through NBS are planned (Alan Smyth,
personal communication), and could significantly contribute to
standards of care within the first years of life of patients identified
by CF NBS. Furthermore, very young, largely asymptomatic
childrenwithCFmay gain themost fromnew drugs for CF,which
have not been fully developed yet, but could become available in
the next few years.
Box 7
CF centre care and the availability of necessary
medication are essential prerequisites before the
introduction of NBS programmes. All newborns
identified by NBS should be managed according to
internationally accepted guidelines.
Harmonising the management of a neonatal
screened CF infant is an ambitious but essential
goal. Steps are being taken to develop guidelines for
the early management of infants identified through
CF NBS. Unresolved issues need to be tackled
through the implementation of specifically designed
longitudinal studies and randomized clinical trials.4. Information to families
Wide variations exist in NBS protocols (IRT/IRT, IRT/
DNA), timing of sample collection, training for personnel
undertaking collection and informing parents about the result,
time taken for the laboratory to produce a result, and methods
by which parents are informed. There are also differences in
how quickly, and by whom, parents are seen after they become
aware of the initial abnormal screening result [74,106].
Therefore, tailoring information to local differences is likely
to best serve parents and reflect the unique circumstances that
have led to variations between the protocols of different regions.
Conversely, parents everywhere have similar needs for
information and there are many basic communication principlesthat will apply equally, regardless of clinical practice. All CFNBS
protocols can be placed into a three-stage schema for parents'
communication needs (Fig. 7). During the time period before
screening, information about CF NBSmay have little salience for
many parentswhose infant on average, has the same risk of having
CF as those of similar ethnicity across the population. In the time
period after confirmatory testing, conversation can be customised
to the infant's actual status (‘CF’, ‘CF-carrier’, or ‘normal’). After
the screening result is communicated, but before the confirmatory
test results are available, lies a “period of maximal uncertainty”
(grey shaded area, Fig. 7). For many parents uncertainty and
salience may both be high during this period.
This Consensus reviewed common principles, results of
relevant research [107] and review [108] and makes recom-
mendations for communication that can be considered across
many different types of screening protocols.
Basic communication principles are outlined by guidelines
such as the Kalamazoo Consensus Statement [109], which
includes elements particularly relevant to the type of information
that is necessary for CF NBS. Firstly, to establish information in a
format that will be easy for parents to digest, the health care
professional should “use language the patient can understand,”
“structure, clarify, and summarize information,” “check for
understanding,” and “encourage questions.” The health care
professional should also “explore [the parents'] beliefs, concerns,
and expectations” in order to tailor information and conversation
style for the needs of the parent. Secondly, in anticipation of
further communication needs, the health care professional should
encourage parental participation “in decisions, to the extent that s/
he desires” as well as “discuss follow-up plans” and “identify and
enlist resources and supports.”
To facilitate parental understanding, irrespective of language
barriers, consideration should be given to using professional
translators. It is not appropriate to rely on limited language skills or
a family member to translate difficult concepts. Health care
professionals informing parents should be knowledgeable about
CF,NBSprinciples, basicCF genetics, and the psychosocial pitfalls
that some parentsmay experience. Health care professionals should
prepare and plan ahead for discussions about NBS results, rather
than improvising. The first words in conversation can be very
important, prompting a suggestion that bad news should be
preceded by an expression of support or other “good news” [109].
Another principle that is particularly important for CF NBS is
that communication must be tailored for each case, focusing on
information that directly applies to the infant and the screening
result, rather than on background information that might be more
suited for a medical student lecture. For example, an extensive
discussion about themanifestations of CF is not likely to be useful
for parents of a CF carrier infant, and may even lead to confusion
about whether the child has CF or is a carrier.
4.1. Before CF NBS
The purpose of providing information before a sample of
blood is taken from the infant is to help parents understand the
process, and its benefits and limitations. This is crucial for those
protocols that are required to obtain prior parental informed
Fig. 7. Time periods common to all CF NBS protocols.
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told about the screening process and potential outcomes of
NBS. Unfortunately, evidence exists that many parents have
limited or no understanding about CF NBS, and are provided
only with sketchy or even no information at busy maternity
units [110–112,42]. In a recent US focus group study of a broad
sample of parents, whilst some recalled receiving a screening
brochure in the hospital after delivery, few reported reading it.
Some stated they remember signing a form that acknowledged
that their infant would have a ‘heel prick test’ but that at the time
of the survey they had retained very little information about
NBS [110]. This lack of knowledge is regrettable because
parents' emotional and cognitive reactions after an abnormal
result are strongly influenced by their prior knowledge about CF
NBS [113], and for many years guidelines have stressed the
importance of parent education [114].
Few NBS programmes have integrated evaluations of the
quality of pre-screening communication and the effectiveness of
information-giving [115], but professionals are increasingly
acknowledging the importance of educating parents about NBS
as well as of the opportunity to ask a knowledgeable health care
professional pertinent questions [47].
Considering when to undertake pre-screening communica-
tion has been challenging for many programmes. Parents are
often educated during the peripartum period [112,106],
presumably following the tradition of having the same health
care professional undertake sample-collection and parent-
education. Yet the peripartum period is associated with many
psychological challenges for parents, with many being unable to
cognitively and emotionally process information on a group of
relatively rare diseases effectively. Many parents reported
feelings of surprise or shock upon being contacted by the
professionals associated with the CF NBS scheme for re-testing.
Others stated that they had not been aware that re-testing was a
possibility or that NBS involved the State Health Department.
Parents may also become angry if the information provided is
incomplete or given too late, especially if they are subsequently
presented with results of investigations that they had not been
told were going to be performed, or if they receive an
unanticipated outcome. Nevertheless, information is unlikely
to be retained if it is provided too early to be relevant to parents.Recently the US Newborn Screening Task Force (2000),
recommended that “pregnant women should be made aware of
the process and benefits of NBS and their right of refusal before
testing, preferably during a routine third trimester prenatal care
visit”. The US College of Obstetrics and Gynaecology
[116,111], have also endorsed counselling by obstetric
providers. Parents in the US focus group study said that they
wanted to hear about NBS from a trusted health care provider,
ideally during the third trimester of pregnancy rather than in the
peripartum period in the hospital. Thus the content, style and
timing of pre-screening counselling, requires careful considera-
tion. Whilst the Consensus Panel's efforts were directed at
communication about CF NBS, of necessity our recommenda-
tions for communication before CF NBS are applicable also to
other diseases. The recommendations are shown in Table 4.
4.2. After a positive NBS test
The point at which parents first hear about an abnormal CF
NBS result can be a critical time, both medically and
psychologically. Unless the infant is found to be homozygous or
compound heterozygote for a CF-causing mutation and therefore
definitely has CF, a key goal of communication during this period
is to facilitate presumptive medical care and confirmatory sweat
testing in a timely fashion. However during this period of
‘maximal uncertainty’, parental anxiety can understandably be
high. Consequently, minimising delay between initial discussion
about an abnormal CF NBS result and diagnostic confirmation is
beneficial for psychological reasons as well as for initiating
medical care and developing mutual trust between the patient's
family and their health care providers [117,34,118].
Many of the same principles discussed earlier apply to
communication during this period. In particular, there should be
an emphasis on consistency and empathy [119]. Parents feel that
this information should be conveyed to them in person by a
knowledgeable health care professional, who is able to answer
appropriate questions and manage parental anxiety [110].
Some programmes have recommended that parents should
be routinely informed about normal NBS results, although some
parents say that they do not wish to be notified about screening
results unless there is a problem [110].
Table 4
Recommendations for counselling before NBS.
1) Communication about CF NBS should be adapted to local protocols. Existing
materials and counselling scripts may be usable at programmes with the
commonly used IRT/DNA/sweat test approach, but programmes using
another screening protocol or confirmatory testing may need to develop their
own communication plan and materials.
2) NBS information should be provided by a trusted health care professional.
3) The panel endorses previous recommendations that couples should be
provided with information about NBS during the third trimester of pregnancy
before labour begins. Ideally the tools and training necessary for effective
communication will be provided to health care professionals caring for the
woman during this trimester.
4) Parental understanding is likely to benefit if information about NBS is given
at multiple times such as prenatal visit, prenatal class and hospital stay.
5) The panel recommends that the pre-NBS conversation should include some
version of the following key messages;
a) Screening is routinely recommended for all newborns babies
b) The primary goal of screening is to identify infants who need early
intervention to improve their health outcomes
c) The testing is safe and does not harm the infant
d) The infant might need to be re-tested (with more specific information being
delivered only if retesting is necessary).
e) These tests are not perfect and that some affected children may be missed
f) Contact information for the provider should be given in case questions arise
6) The panel endorses the recommendation of parent focus groups that the health
care professional should not discuss all of the NBS diseases with parents, as
too much information can increase anxiety. Parents wanted only essential
information, this being presented as briefly and as simply as possible.
7) To support parents with a language barrier or limited health literacy, and to
serve as a memory aid, verbal information should be supplemented with other
communication media (e.g., leaflets, videos, or CD-ROMs). The usefulness of
these tools should be evaluated and refined prior to widespread use.
8) The panel recommends that written information about NBS should be
provided to parents and include some version of the following questions and
answers (adapted from 110).
a) Q:Why does my baby need NBS testing? A:Most babies are healthy when
they are born. We test all babies because a few look healthy but have a rare
health problem. If we find problems early, we may prevent some of them
becoming serious.
b) Q:How will my baby be tested? A: In the first week of life a nurse will take
a few drops of blood from your baby's heel. The hospital will send the blood
sample to a newborn screening laboratory for testing.
c) Q: How will I get the results of the test? A: Parents are notified of test
results within the first 2 months if there is a problem. Ask about results when
you see your health care professional.
d) Q: Why do some babies need to be re-tested? A: Some babies need to be
re-tested for a variety of reasons. If your baby needs a re-test your heath care
professional will discuss this with you. If the initial test was performed before
your baby was 48 h old, then re-testing may be routine.
e) Q: What will happen if my baby needs to be re-tested? A: For some
conditions re-testing is urgent because if necessary, treatment needs to be
started as soon as possible. Make sure that the person doing the screening test
has the correct contact details for you and your primary care provider.
f) Q: What if I have questions? A: Ask your health care professional if you
have questions or concern.
Table 5
Recommendations for counselling about positive NBS results.
1) Information given to parents about positive NBS results must be adapted to
reflect local protocols and the results' significance. To facilitate this, as an
inherent part of the program, health care professionals should be educated on
the significance of the NBS result and written reminder materials should be
attached to the NBS result.
2) Ideally parents should be informed about the positive NBS result in person. If
this is not possible, the person communicating by letter or telephone should be
extremely careful about wording and be aware that parents may be prone to
misunderstanding and psychological problems.
3) It is important to emphasise that a raised (positive), screening test result is not
confirmation of a diagnosis of CF. Further tests will be needed to confirm or
exclude the diagnosis of CF. A parent of a child who has a raised IRT and a
positive DNA test (in some programmes an elevated IRT alone), will need to
be informed of the need for further investigation.
4) Delays should be minimised. Ideally, no more than 48 h should pass between
the moment the parent is aware of the result to the time of expert assessment
and confirmatory testing.
5) Minimising delays should not be at the expense of intentionally alarming
parents about the potential for CF-related complications. Whilst this may be
common practice for NBS diseases with a more emergent time course, it is not
necessary for CF NBS.
6) The health care professional undertaking the counseling of parents should be
knowledgeable about CF NBS and genetics, and have had training in
cautious, empathic communication skills.
The following three statements are protocol-specific and their inclusion depends
on the relative probability that the child has CF.
7) Ideally, both parents should be present when the diagnosis of CF is first
communicated and explained. If only one of the infant's parents can be
present then it is strongly advised that a supportive family member or friend
should accompany the parent to the appointment.
8) Health care professionals should be aware that parents are more likely to
understand information provided if initial counselling focuses on conveying a
few high-value messages rather than attempting to fully educate the parent
about every aspect of CF and NBS.
9) The panel recommends that the post-NBS, pre-diagnosis conversation and
written materials should include a review of points made before NBS, plus
some version of the following messages, questions and answers.
a) Q: What does my baby's screening result mean? A: The screening results
suggest your baby has cystic fibrosis (CF), although further tests will be
needed to confirm or exclude this.
b) Q: What happens next? A: We need to do a more detailed assessment, but
otherwise your baby does not need any urgent treatment or special care from
you now. The most important step is to see the doctor about further tests for
your baby. You have an appointment to see a doctor who is a specialist in
children with CF. They will examine your baby and, if necessary, arrange
further tests. They will explain the results to you.
c) A repeat sample/test may be needed because of an initial inadequate test
(e.g. multiple drops, inadequate sample, technical error), a previous false-
positive result or a probable diagnosis of CF.
d) Q: What is CF? A: CF is a hereditary condition which mainly affects the
lungs and digestive system. Children born with it are susceptible to chest
infections and may not put on weight like they should.
e) Q:What treatment is available for CF? A: Screening means that babies can
be treated early with an appropriate diet, medicines and chest physiotherapy.
Treatments are improving all the time.
f) Q: How do you feel? A: You may feel a sense of shock, disbelief, anger, or
fear. These reactions are normal. Remember it is not yet known for certain that
your baby has CF. We will make sure that all your questions answered.
g) [Inform the parent where they may access other sources of information and
support (tailored to local resources). Provide some cautionary advice about
information that might be found on the Internet].
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positive NBS results are shown in Table 5.
4.3. At diagnosis
The purpose of communication at this point is to set the
context for the infant's medical care, surveillance for pulmonary
and nutritional complications and whether or not further tests ortreatments are necessary. Communication should be sensitive to
parents' emotions, although fortunately research has shown
that, on average, early diagnosis does not interfere with mother–
Table 7
Recommendations for counselling parents when CF NBS identifies carrier
infants.
What is my baby's screening result?
The screening result suggests that your baby is a carrier of CF. Approximately 1
in every 20 to 37 healthy people are carriers of a mutation in the CF gene.
What does it mean to be a carrier of the CF gene?
Your baby is just like one of his or her parents and has only one copy of a
mutated CF gene.
To have CF you need two copies of a mutated CF gene passed from each of the
baby's carrier parents.
How will being a carrier affect my child?
Your child will not be affected by the condition and will not need any special
treatment. ‘Carriers’ can pass on the altered gene to their children and you
may wish to tell your child this when they are older.
What is CF?
Children with CF are susceptible to chest infections and may not put on weight
like they should.
Is it possible that my child does have CF?
The answer to this question is determined to some extent by the CF NBS
programme. However, the screening test is not perfect and there is a very
small risk that your baby has CF. There are uncommon mutations in the CF
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feelings of closeness [120].
The Consensus recommendations for a positive diagnosis of
CF are shown in Table 6.
4.4. For parents of carrier infants
Identification of carrier status is not the goal of CF NBS but
rather an important consequence of it. Carrier infants are healthy,
but as adults can pass on their mutated CFTR gene to their own
offspring who may end up having the disease, if their partner is
also a carrier. Inevitably carriers are identified inNBSprogrammes
that utilise DNA-based techniques for screening. However, since
they often have higher neonatal IRT values than non-carriers
[121], programmes that only use IRT techniques may also lead to
the use of DNA testing and identification of carrier infants.
Psychosocial complications of identifying carrier-status are
so severe and common that it has been argued that, for suchTable 6
Recommendations for communicating with parents following a positive
diagnosis of CF.
The first consultation with the parents of a child with CF is very important and
may set the scene for the future relationship with the CF team and the parents'
perception and expectations of their child's future.
It is essential that the CF team members involved in the initial discussion
regarding CF are fully informed about CF and are able to appropriately
answer questions posed by parents.
Early and repeat consultations to discuss all of the above issues are essential.
It is important that the parents understand that the future care of their child
depends on a partnership between themselves and the CF team.
Most CF services have access to written information published by national CF
organisations. It is appropriate to use this written information to supplement
counselling. It may be in the form of several different leaflets. It is important
to ask questions of an informed health care professional.
The time lag from the moment a parent of an infant with a suggestive screening
test is made aware of the concern that their child may have CF, until the
appointment with a CF expert at a specialist clinic, should be less than 48 h.
Written information should address the following topics.
What is CF?
CF is a common genetic disorder. Children with CF are susceptible to chest
infections and may not put on weight like they should. Contemporary care
means that babies born today can expect to live fulfilling adult lives.
How will my child be medically taken care of?
CF care involves a multidisciplinary team including; doctors, nurses,
physiotherapists and dietitians as well as other health care professionals
(e.g., pharmacists, microbiologists psychologists and social workers).
Treatments are best explained by the CF team.
How to deal with CF in daily life?
Developing good routines is an important aspect of your child's development.
These should be no different from children without CF, with the exception of
incorporating CF care into family life. Going to school, interacting with
family and friends and engaging in recreational and sporting activities, are all
positively encouraged.
What about siblings and future reproductive issues?
It is important to include siblings in some aspects of CF care. Families who do
well are the ones which undertake CF care routinely and who attend to their
own needs as well as those of their child with CF.
With regards to future reproductive choices and decision-making, these issues
can be discussed in time with the CF team and in genetic counseling.
gene that are not recognised by the screening test. It is therefore possible that a
baby with this result will have a second, uncommon CF gene mutation and
will have CF.
If you are worried about the result you should discuss this issue with your family
doctor.
If we have children in the future, could they have CF?
Your baby has been recognised to be a carrier of CF, but there is an increased risk
that if you have children in the future they may have CF. Accessing genetic
counselling is preferable and could be important before planning further
pregnancies.
Who else can I talk to about my baby's screening result?
You can discuss this with your health care professional.
Where can I find more information or support?
[INSERT Local CF Association address, phone and website].parents, effective communication may be the only way to
“ensure more good than harm” [122]. The purpose of
communication at this point is to ensure that the parent
understands that the infant is healthy and does not have CF and
that they defer knowledge of the baby's carrier status to
adulthood. Preparation for discussions with relatives has also
to be considered. Reviews of the psychological impact of
parents being told of their infant's carrier-status [108], suggest
that:
• Parental retention of knowledge over the longer-term is
unreliable, with a high proportion of misconceptions over
carrier-status and its implications [47].
• Whilst parents might be satisfied with the quality of
information they received, a high proportion can have
lingering anxiety about their child's health and their own
future reproductive decision-making despite further sugges-
tion that NBS does not lead to changes in subsequent
pregnancy planning [123].
• Some parents have concerns about talking to extended
family members about ‘carrier’ status, predominantly due to
CF being a genetic diagnosis, and the topic having the
potential to accentuate dysfunctional family relationships
and create new stresses [124–126,107] even though
170 C. Castellani et al. / Journal of Cystic Fibrosis 8 (2009) 153–173subsequent cascade testing is reported to not be utilised
frequently by extended family members [123].
The Consensus recommendations for counselling parents
when carrier infants are detected are shown in Table 7.
Box 8
Effective communication between health care
providers and parents is central to the success of CF
NBS. The standard for communication must cover
pre-screening information to families, and informa-
tion for parents of NBS positives, neonates with CF,
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